Drug intelligence / Profile preview

HXASP028

Development stage: Unknown
Lead developer: Guangxi Shanhe Baisheng Technology
Modality: Small Molecules
Administration: Oral

Overview

HXASP028 is an oral granule formulation of aspirin (acetylsalicylic acid) being developed by Guangxi Shanhe Baisheng Technology. It is designed for the treatment of Kawasaki disease, a condition characterized by systemic inflammation of blood vessels where aspirin is used for its anti-inflammatory and anti-platelet properties. The drug is currently in Phase 1 clinical development, with studies focusing on its pharmacokinetic profile and bioequivalence compared to standard aspirin enteric-coated tablets. Like traditional aspirin, HXASP028 works by irreversibly inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby blocking the production of thromboxane A2 and prostaglandins.

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on HXASP028.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HXASP028.

Explore the full profile